Marek Ziobro
YOU?
Author Swipe
View article: Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights Open
Background Sacituzumab govitecan (SG) is approved for advanced triple-negative breast cancer (TNBC) in the second-line setting and beyond, offering improved survival compared to chemotherapy. Adverse events (AEs) commonly include myelosupp…
View article: Incidence and prevalence of organ toxicities in patients suffering from clear cell renal carcinoma treated with sunitinib and its impact on survival: a reference cancer center experience
Incidence and prevalence of organ toxicities in patients suffering from clear cell renal carcinoma treated with sunitinib and its impact on survival: a reference cancer center experience Open
Introduction Tyrosine kinase inhibitors (TKIs) are the standard treatment options for advanced clear cell renal cell carcinoma (ccRCC), but their toxicities can hinder optimal dosing, affecting clinical outcomes. Material and methods A ret…
View article: Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohort
Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohort Open
Background: Body mass index (BMI) and weight change are commonly explored as prognostic factors in breast cancer. However, their impact on outcomes with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) remains…
View article: Primary breast adenoid cystic carcinoma — insights from a 4-case series
Primary breast adenoid cystic carcinoma — insights from a 4-case series Open
INTRODUCTION: Adenoid cystic carcinoma (AdCC) of the breast is a rare, slow-growing yet locally aggressive malignancy,often exhibiting a triple-negative immunophenotype. This study evaluated the clinical and pathological aspectsof primary …
View article: Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in the Polish cancer patient population
Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in the Polish cancer patient population Open
The Polish versions of the IN-PATSAT32 and QLQ-INFO25 are reliable and valid instruments providing domains not covered by the core EORTC module. These tools are suitable for use in daily clinical practice, in research as well as in clinica…
View article: Time from Final Oncologist Visit to Death and Palliative Systemic Treatment Use Near the End of Life in Heavily Pretreated Patients with Luminal Breast Cancer
Time from Final Oncologist Visit to Death and Palliative Systemic Treatment Use Near the End of Life in Heavily Pretreated Patients with Luminal Breast Cancer Open
Background: Palliative care must be tailored for patients with extended disease trajectories, such as those with hormone receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC), including th…
View article: Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study
Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study Open
The standard therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer includes the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy. The optimal post-CDK4…
View article: Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study
Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study Open
Background and purpose: Metaplastic breast carcinoma (BC-Mp) is an uncommon subtype that poses unique challenges. The limited information on patient prognosis and therapeutic strategies motivated our research initiative. We aimed to assess…
View article: Knowledge and awareness of cervical cancer and prevention measures among female students in Poland: a cross-sectional, decade apart study
Knowledge and awareness of cervical cancer and prevention measures among female students in Poland: a cross-sectional, decade apart study Open
The insufficient knowledge and deteriorating trends in CC prevention among young women over the last decade are concerning. The proportion of vaccinated women remains unsatisfactory. Measures to enhance awareness of national reimbursed HPV…
View article: Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis Open
Due to the hepatotoxicity of BC-active drugs, specific recommendations for systemic treatment are scarce. Our study explored cisplatin's potential use, finding it to be a viable option in patients with performance status 0 or 1 experiencin…
View article: Non-metastatic primary neuroendocrine neoplasms of the breast: a reference cancer center’s experience of a heterogenous entity
Non-metastatic primary neuroendocrine neoplasms of the breast: a reference cancer center’s experience of a heterogenous entity Open
Background Primary neuroendocrine neoplasms of the breast (Br-NENs) are rare. The classification has been updated in recent years making interpretation of the data published challenging. It is unclear whether neuroendocrine differentiation…
View article: Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience
Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience Open
Metaplastic breast cancer (BC-Mp), which includes a range of epithelial and mixed epithelial-mesenchymal tumours, are rare malignancies with an unfavourable prognosis. The limited literature on BC-Mp focuses mainly on retrospective data fo…
View article: Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients
Discrepancy between Tumor Size Assessed by Full-Field Digital Mammography or Ultrasonography (cT) and Pathology (pT) in a Multicenter Series of Breast Metaplastic Carcinoma Patients Open
Metaplastic breast cancer (BC-Mp) presents diagnostic and therapeutic complexities, with scant literature available. Correct assessment of tumor size by ultrasound (US) and full-field digital mammography (FFDM) is crucial for treatment pla…
View article: Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in Polish cancer patients’ population
Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in Polish cancer patients’ population Open
Background: The IN-PATSAT32 and QLQ-INFO25 are questionnaires which can be applied to assess and improve communication with cancer patients, as well as for research and clinical trials aimed at assessing patients’ satisfaction and percepti…
View article: Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective
Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective Open
Patients with hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer constitute about 70% of the breast cancer population. About 35% of these patients develop distant metastases and their tre…
View article: Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience
Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience Open
Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated wi…
View article: Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population Open
Trastuzumab-induced cardiotoxicity (TIC) can lead to early treatment discontinuation. The aim of this study was to evaluate: N-terminal brain natriuretic peptide (NT-proBNP), creatine kinase-MB (CK-MB), myoglobin, and selected biochemical …
View article: Adjuvant combined therapy with trastuzumab in patients with HER2-positive breast cancer and cardiac alterations: implications for optimal cardio-oncology care
Adjuvant combined therapy with trastuzumab in patients with HER2-positive breast cancer and cardiac alterations: implications for optimal cardio-oncology care Open
Asymptomatic subclinical cardiac alterations during TT may predict late cardiac complica-tions; however, longer follow‑up is necessary to confirm this hypothesis. Patients with HER2‑positive BC should be closely monitored for possible card…
View article: Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy
Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy Open
Immune checkpoint inhibitors have significantly improved the prognosis of melanoma patients. However, these therapies may trigger unexpected immune-related adverse events (irAEs), which are challenging in making the proper diagnosis and pr…
View article: Low frequency of HPV positivity in breast tumors among patients from south-central Poland
Low frequency of HPV positivity in breast tumors among patients from south-central Poland Open
Background Some studies suggest that Human Papilloma Virus (HPV) infection is important factor in carcinogenesis of breast tumors. This study’ objective was to analyze HPV prevalence in breast cancers of patients from south-central Poland.…
View article: Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma Open
PURPOSE Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non–clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and sa…
View article: Primary cardiac atrial sarcomas. Report of two histologically different cases and review of the literature
Primary cardiac atrial sarcomas. Report of two histologically different cases and review of the literature Open
Primary cardiac sarcomas are extremely uncommon. We report two patients with primary cardiac atrial sarcomas: a case report of a 34-year old woman with intimal sarcoma of the left atrium and a case report of a 30-year old man with synovial…